CIPLA.NS

Cipla Limited [CIPLA.NS] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

CIPLA.NS Stock Summary

EPS has been increasing for the past 3 years (Yearly statements)

Earnings are expected to fall -100% next year

CIPLA.NS has less than 1 year of cash runway

Top 10 Correlated Stocks

CIPLA.NS

In the News

CIPLA.NS Financial details

Company Rating

Buy

Market Cap

1127.73B

Income

37.08B

Revenue

250.3B

Book val./share

Cash/share

Dividend

8.5

Dividend %

0.64%

Employees

32.32K

Optionable

Shortable

Yes

Earnings

10 May 2024

P/E

54.28

Forward P/E

PEG

11.5

P/S

8.15

P/B

4.32

P/C

P/FCF

2750.45

Quick Ratio

2.22

Current Ratio

3.37

Debt / Equity

LT Debt / Equity

EPS (TTM)

45.93

EPS next Y

EPS next Q

EPS this Y

11.28%

EPS next Y

EPS next 5Y

EPS last 5Y

12.85%

Revenue last 5Y

7.01%

Revenue Q/Q

-1.27%

EPS Q/Q

-6.64%

SMA20

-5.14%

SMA50

1.67%

SMA100

13.78%

Inst Own

Inst Trans

ROA

ROE

16%

ROC

0.13%

Gross Margin

66%

Oper. Margin

25%

Profit Margin

15%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

896.3-1519.0

52W High

-11.41%

52W Low

+50.2%

RSI

Rel Volume

0.73

Avg Volume

1.62M

Volume

1.17M

Perf Week

-7.98%

Perf Month

-9.21%

Perf Quarter

16.94%

Perf Half Y

14.68%

Beta

0.368

Volatility

35.51%, 43.52%

Prev Close

-0.12%

Price

1345.75

Change

-2.2%

CIPLA.NS Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-03-31

Metric	2019-03-31	2020-03-31	2021-03-31	2022-03-31	2023-03-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	198.87	207.24	235.59	268.17	278.48
Net income per share	18.97	19.19	29.82	31.2	34.72
Operating cash flow per share	21	38.07	46.57	41.23	40.12
Free cash flow per share	14.45	25.66	36.41	32.54	25.46
Cash per share	32.71	21.82	39.1	57.42	83.46
Book value per share	186.4	195.57	227.28	258.37	290.06
Tangible book value per share	131.21	139.24	170.52	201.78	237.91
Share holders equity per share	186.4	195.57	227.28	258.37	290.06
Interest debt per share	55.63	40.67	26.88	14.39	11.31
Market cap	423.34B	340.82B	657.26B	821.23B	726.71B
Enterprise value	461.42B	364.29B	669.47B	825.01B	728.47B
P/E ratio	27.71	22.04	27.33	32.63	25.94
Price to sales ratio	2.64	2.04	3.46	3.8	3.23
POCF ratio	25.03	11.11	17.5	24.69	22.45
PFCF ratio	36.37	16.48	22.38	31.29	35.37
P/B Ratio	2.82	2.16	3.59	3.94	3.1
PTB ratio	2.82	2.16	3.59	3.94	3.1
EV to sales	2.88	2.18	3.52	3.81	3.24
Enterprise value over EBITDA	13.08	10.47	15.07	17.5	13.24
EV to operating cash flow	27.28	11.87	17.83	24.81	22.5
EV to free cash flow	39.64	17.61	22.8	31.43	35.45
Earnings yield	0.04	0.05	0.04	0.03	0.04
Free cash flow yield	0.03	0.06	0.04	0.03	0.03
Debt to equity	0.29	0.2	0.11	0.05	0.03
Debt to assets	0.18	0.13	0.08	0.04	0.03
Net debt to EBITDA	1.08	0.67	0.27	0.08	0.03
Current ratio	3.29	2.66	2.88	3	3.38
Interest coverage	12.46	11.2	21.24	33.98	36.59
Income quality	0.81	1.41	1.14	0.9	0.77
Dividend Yield	0.01	0.02	0	0	0.01
Payout ratio	0.16	0.36	0.01	0.16	0.14
Sales general and administrative to revenue	0.04	0.05	0.04	0.04	0.04
Research and developement to revenue	0.02	0.02	0.01	0.01	0.02
Intangibles to total assets	0.2	0.2	0.19	0.18	0.15
Capex to operating cash flow	-0.31	-0.33	-0.22	-0.21	-0.37
Capex to revenue	-0.03	-0.06	-0.04	-0.03	-0.05
Capex to depreciation	-0.4	-0.85	-0.77	-0.71	-1.01
Stock based compensation to revenue	0	0	0	0	0
Graham number	282.06	290.57	390.53	425.88	476.02
ROIC	0.08	0.08	0.12	0.12	0.11
Return on tangible assets	0.08	0.08	0.12	0.11	0.11
Graham Net	4.5	6.39	36.64	60.44	86.3
Working capital	86.55B	73.13B	86.18B	98.14B	121.65B
Tangible asset value	105.67B	112.23B	137.5B	162.77B	192B
Net current asset value	38.08B	41.01B	66.43B	87.44B	115.25B
Invested capital	0.29	0.2	0.11	0.05	0.03
Average receivables	53.11B	56.92B	54.7B	50.57B	46.36B
Average payables	20.52B	21.39B	21.9B	23.04B	24.89B
Average inventory	40.05B	41.71B	45.23B	50.1B	52.53B
Days sales outstanding	132.64	121.56	103.33	79.92	73.65
Days payables outstanding	113.93	126.61	95	99.68	108.68
Days of inventory on hand	227.51	241.75	212.49	211.58	228.07
Receivables turnover	2.75	3	3.53	4.57	4.96
Payables turnover	3.2	2.88	3.84	3.66	3.36
Inventory turnover	1.6	1.51	1.72	1.73	1.6
ROE	0.1	0.1	0.13	0.12	0.12
Capex per share	-6.55	-12.41	-10.16	-8.69	-14.66

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q3

Metric	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	-66.25	70.2	77.66	81.62	80.58
Net income per share	-8.35	6.51	12.33	14.01	13.08
Operating cash flow per share	6.74	0.48	5.93	7.19	5.78
Free cash flow per share	6.74	0.48	5.93	7.19	5.78
Cash per share	51.86	83.44	77.59	88.87	0
Book value per share	274.67	290.01	293.76	307.5	0
Tangible book value per share	0	237.87	0	255.55	0
Share holders equity per share	274.67	290.01	293.76	307.5	0
Interest debt per share	-0.14	10.38	0.2	12.22	0.37
Market cap	868.44B	726.84B	819.31B	957.61B	1010B
Enterprise value	910.3B	728.59B	881.94B	959.22B	1010B
P/E ratio	-32.2	34.57	20.57	21.17	23.91
Price to sales ratio	-16.24	12.83	13.07	14.53	15.52
POCF ratio	159.58	1.86K	171.25	165.08	216.34
PFCF ratio	159.58	1.86K	171.25	165.08	216.34
P/B Ratio	3.92	3.11	3.46	3.86	0
PTB ratio	3.92	3.11	3.46	3.86	0
EV to sales	-17.02	12.86	14.07	14.56	15.52
Enterprise value over EBITDA	-104.82	55.69	54.1	50.22	52.27
EV to operating cash flow	167.27	1.87K	184.34	165.36	216.34
EV to free cash flow	167.27	1.87K	184.34	165.36	216.34
Earnings yield	-0.01	0.01	0.01	0.01	0.01
Free cash flow yield	0.01	0	0.01	0.01	0
Debt to equity	0	0.03	0	0.04	0
Debt to assets	0	0.03	0	0.03	0
Net debt to EBITDA	-4.82	0.13	3.84	0.08	0
Current ratio	0	3.38	0	3.37	0
Interest coverage	50.84	28	76.55	62.79	56.44
Income quality	0.68	0.07	0.48	0.51	0.44
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0.01	0	0	0
Research and developement to revenue	-0.07	0.07	0.06	0.06	0.06
Intangibles to total assets	0	0.15	0	0.14	0
Capex to operating cash flow	0	0	0	0	0
Capex to revenue	0	0	0	0	0
Capex to depreciation	0	0	0	0	0
Stock based compensation to revenue	0	0.01	0	0	0
Graham number	227.23	206.14	285.53	311.32	0
ROIC	-0.02	0.03	0.04	0.05	0
Return on tangible assets	0	0.02	0	0.04	0
Graham Net	51.86	86.28	77.59	95	0
Working capital	41.86B	121.65B	62.63B	133.59B	0
Tangible asset value	0	192B	0	206.31B	0
Net current asset value	41.86B	115.25B	62.63B	127.26B	0
Invested capital	0	0.03	0	0.04	0
Average receivables	19.85B	22.67B	22.67B	26.95B	26.95B
Average payables	12B	12.29B	12.29B	13.38B	13.38B
Average inventory	27.2B	25.78B	25.78B	27.35B	27.35B
Days sales outstanding	0	72.03	0	73.61	0
Days payables outstanding	0	107.17	0	104.1	0
Days of inventory on hand	0	224.91	0	212.84	0
Receivables turnover	0	1.25	0	1.22	0
Payables turnover	0	0.84	0	0.86	0
Inventory turnover	0	0.4	0	0.42	0
ROE	-0.03	0.02	0.04	0.05	0
Capex per share	0	0	0	0	0

CIPLA.NS Dividend History

CIPLA.NS Frequently Asked Questions

What is Cipla Limited stock symbol ?

Cipla Limited is a IN stock and trading under the symbol CIPLA.NS

What is Cipla Limited stock quote today ?

Cipla Limited stock price is $1345.75 today.

Is Cipla Limited stock public?

Yes, Cipla Limited is a publicly traded company.

Something similar

Top by Market Cap

Same Sector

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 1.62M
Market Capitalization 1127.73B
Employee 32.32K
CEO Mr. Umang Vohra B.E., M.B.A.
Headquarters Mumbai,IN
IPO Date 1996-01-01
Website https://www.cipla.com

Cipla Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India, the United States, South Africa, and internationally. The company offers active pharmaceutical ingredients; and formulations in various therapeutic areas, such as MI, angina, heart failure, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, HIV, respiratory, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. It also provides respiratory products, including inhalers and nasal sprays, as well as other respiratory products consists of injectables and biosimilars. Cipla Limited has a licensing agreement with Merck & Co., Inc. for the manufacturing and distribution of Molnupiravir, an investigational oral antiviral drug; a license agreement with Eli Lilly and Company for the manufacture and commercialization of the drug baricitinib for Covid-19 indication; and collaborations with Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Limited, Emcure Pharmaceuticals Limited, and Torrent Pharmaceuticals Limited for the clinical trial of the investigational oral anti-viral drug Molnupiravir. The company was incorporated in 1935 and is headquartered in Mumbai, India.